Ascendis Pharma A/S (ASND) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-02

Ascendis Pharma A/S (ASND) has filed 5 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-02. 1 Form 144 notices of proposed sale were filed for ASND stock. InsiderAlpha tracks every ASND SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Ascendis Pharma A/S (ASND)

SEC CIK	0001612042

90-Day SEC Filing Activity

Form 4 filings (90d)	5
Form 144 notices (90d)	1
Latest Form 4 filing	2026-06-02

Recent ASND Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-02	SMITH SCOTT THOMAS	EVP & Chief Financial Officer	P — Open-market purchase	100	$219.00	$22K	SEC
2026-05-29	BIENAIME JEAN JACQUES	Insider	P — Open-market purchase	200	$222.30	$44K	SEC
2026-05-29	BIENAIME JEAN JACQUES	Insider	P — Open-market purchase	200	$223.76	$45K	SEC
2026-05-29	BIENAIME JEAN JACQUES	Insider	P — Open-market purchase	100	$223.50	$22K	SEC
2026-05-29	SMITH SCOTT THOMAS	EVP & Chief Financial Officer	P — Open-market purchase	250	$223.32	$56K	SEC
2026-05-26	BIENAIME JEAN JACQUES	Insider	P — Open-market purchase	200	$239.37	$48K	SEC
2026-05-26	BIENAIME JEAN JACQUES	Insider	P — Open-market purchase	200	$236.24	$47K	SEC
2026-05-11	JENSEN FLEMMING STEEN	See Remarks	S — Open-market sale	19.5K	$238.49	$4.64M	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Ascendis Pharma A/S (ASND). Updated in real time as new filings are submitted to the SEC.

Most-Active ASND Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
BIENAIME JEAN JACQUES	5	$207K
SMITH SCOTT THOMAS	2	$78K
JENSEN FLEMMING STEEN	1	$4.64M

Recent ASND Form 144 Notices of Proposed Sale

2026-05-11 — — [SEC]

Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.

Recent Insider Filings

2026-06-02 — SMITH SCOTT THOMAS (EVP & Chief Financial Officer)
2026-06-01 — BIENAIME JEAN JACQUES (Insider)
2026-06-01 — SMITH SCOTT THOMAS (EVP & Chief Financial Officer)
2026-05-27 — BIENAIME JEAN JACQUES (Insider)
2026-05-12 — JENSEN FLEMMING STEEN (See Remarks)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ASND insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

ASND Insider Trading — FAQ

What is the latest insider trade for ASND?: Ascendis Pharma A/S (ASND) had 5 insider filings in the last 90 days, with the most recent on 2026-06-02. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying ASND stock?: 0 insider purchases of ASND were filed in the last 90 days.
How many insiders are selling ASND stock?: 0 insider sales of ASND were filed in the last 90 days.
Where can I see ASND SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every ASND SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live ASND dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.